Ann: Long Covid-19 Collaboration Outcomes Presentation, page-18

So, the ASX wanted to see "data"....and ANP said no cos this is not a 'clinical study'....AND...the Biomarkers identified are "TRADE SECRETS".

Those of us who have been following the MS and DMD story already know what the Biomarkers are...but i'm guessing they have identified many more!

The ASX then asked about the patents:

3. Please provide details of the patent applications referred to in the Draft Market Release. The titles of the three patent applications are:

“Biomarkers and Uses thereof”

“Methods for treating neurological post-acute sequelae of COVID-19 (NPASC)”

“Methods for diagnosing and treating neurological post-acute sequelae of COVID-19 (NPASC)”

Wow - this is exciting stuff folks!

With so much intense interest in long covid - you would think Pfizer and other Big Pharma would at least take a look?

This is good science that will add shareholder value....

Now - when are we listing in NASDAQ?
.